Objective: To determine the mortality of Crohn disease (CD) and ulcerative colitis (UC) and temporal trends in mortality. Patients and Methods: All 895 residents of Olmsted County, Minnesota, first diagnosed as having inflammatory bowel disease (IBD) (411 with CD and 484 with UC) from January 1, 1970, through December 31, 2010, were followed through June 30, 2016. Standardized mortality ratios (SMRs) were computeddexpected rates were derived from the US 2010 background population. To determine overall and cause-specific mortality, each patient with IBD was matched with 5 county residents, and Cox regression analysis was used to assess time to death. Results: A total of 895 patients with IBD and 4475 patients without IBD were included. Seventy-four patients with CD died compared with 59.2 expected (SMR, 1.25; 95% CI, 0.98-1.57), and 77 patients with UC died compared with 108.1 expected (SMR, 0.71; 95% CI, 0.56-0.89). In CD, the risk of dying was significantly associated with diagnosis from 1970 through 1979 (SMR, 1.90; 95% CI, 1.24-2.78). Of those diagnosed after 1980, the risk of dying in patients with CD was similar to the US background population. In UC, the risk of dying was less than expected in all periods of diagnosis. In the Cox regression analysis, overall mortality was not significantly higher in CD (hazard ratio [HR], 1.26; 95% CI, 0.97-1.63) or UC (HR, 0.89; 95% CI, 0.70-1.14) compared with the comparison cohort. The risk of dying of digestive diseases (HR, 3.70; 95% CI, 1.24-11.0) and respiratory diseases (HR, 2.72; 95% CI, 1.36-5.44) was increased in CD but not UC. Conclusion: In this cohort, overall mortality in patients with CD diagnosed after 1980 did not differ from that in the US background population. Overall mortality in patients with UC diagnosed from 1970 through 2010 was lower than the expected mortality.
D
uring the past 2 decades, the management of inflammatory bowel disease (IBD) has changed substantially due to increased use of immunomodulators, earlier introduction of biological agents, improvements in surgical techniques, and increased awareness of colorectal cancer (CRC) surveillance. 1, 2 On the other hand, some of the medications used to treat IBD may cause serious adverse effects, such as an increased risk of serious infection or malignancy. [3] [4] [5] Thus, the impact of more effective management of IBD on the "hard end point" of mortality remains unknown.
The overall impact of IBD on long-term mortality in IBD varies worldwide. Recently, studies from the Netherlands, 6 Norway, 7 Australia, 8 and Korea 9 demonstrated that mortality rates in Crohn disease (CD) and ulcerative colitis (UC) were comparable with those in their respective general populations. In contrast, population-based studies in Canada, 10 Denmark, 11 and Finland 12 reported that all-cause mortality in IBD was increased in patients with CD and in those with UC. 10, 12 In addition, data regarding mortality trends over time vary from country to country. A nationwide Danish study of mortality trends from 1982 to 2010 showed that the mortality in patients with UC decreased, but the mortality trend in CD remained stable during the study period. 13 In contrast, a study from Canada reported a decreasing mortality trend in CD and UC between 1999 and 2008. 10 One potential explanation for this variation in results could be different study designs.
Thus, a population-based cohort in a welldefined geographic area targeting incident cases and following the natural history would be useful in studying long-term mortality and temporal trends. The mortality of a population-based cohort of patients with IBD from Olmsted County, Minnesota, that had been diagnosed from 1940 through 2001 has been previously reported. 14 Although not statistically significant, the mortality rate in patients with CD was higher than that expected in the US white population (standardized mortality ratio [SMR], 1.2; 95% CI, 0.9-1.6).The overall survival of patients with UC was similar to or better than that expected in the US white population (SMR, 0.8; 95% CI, 0.6-1.0).
14 After a period of improvement in the management of IBD, a more recent study of changes in mortality over time in a US populationbased IBD cohort has not been performed. The aim of this study was to reevaluate overall mortality and temporal trends in this population-based cohort of patients with IBD.
METHODS

Rochester Epidemiology Project
The resources of the Rochester Epidemiology Project (REP) were used to identify permanent residents of Olmsted County who were diagnosed as having IBD. This unique medical records linkage system was developed in the 1960s and has been continuously funded by the National Institutes of Health since its inception. 15 It exploits the fact that virtually all of the health care for the residents of Olmsted County is provided by 2 organizations: Mayo Medical Center, consisting of Mayo Clinic and its 2 affiliated hospitals (Rochester Methodist and St Marys), and Olmsted Medical Center, consisting of a smaller multispecialty clinic and its affiliated hospital (Olmsted Community Hospital). In any 4-year period, more than 95% of county residents are examined at either of the 2 health care systems. 16, 17 Diagnoses generated from all outpatient visits, emergency department visits, hospitalizations, nursing home visits, surgical procedures, autopsy examinations, and death certificates are recorded in a central diagnostic index. Thus, it is possible to identify all diagnosed cases of a given disease for which patients sought medical attention. 17 
Case Ascertainment
The institutional review boards of Mayo Clinic and Olmsted Medical Center approved the protocol. The study cohort comprised 895 Olmsted County residents first diagnosed as having IBD from January 1, 1970, through December 31, 2010, according to welldefined criteria as previously described. [18] [19] [20] [21] All the patients were followed from diagnosis until death, emigration, or the end of the study (June 30, 2016), whichever came first. For all deceased patients, death certificates were retrieved to identify cause of death based on the International Classification of Diseases, Tenth Revision codes, and medical records were reviewed to confirm the cause of death. To determine death related to IBD, 2 gastroenterologists (E.V.L. and S.A.) discussed all the cases. The following data were recorded: date of birth, sex, date of IBD diagnosis, IBD phenotype at diagnosis, date of last followup, date of death, and cause of death.
Statistical Analyses
Overall survival in the cohort was estimated using the Kaplan-Meier method. Overall mortality risk was calculated in 2 ways. The SMRs (observed deaths/expected deaths) were computeddexpected deaths were derived from age-and sex-specific mortality rates in the US 2010 background population according to the US Census Bureau. The SMR analysis was stratified by sex, age at IBD diagnosis (0-18, 19-29, 30-49, and 50 years), and calendar period of IBD diagnosis (1970-1979, 1980-1989, 1990-1999, and 2000-2010) . Second, to evaluate overall and cause-specific mortality in the cohort, each patient with IBD was age-, sex-, and index date of IBD diagnosisematched with 5 Olmsted County residents who did not have IBD. We chose 5 matched comparisons for each case to improve statistical power; however, after 4 or 5 comparisons, not much incremental statistical power is gained by additional comparisons. Cox proportional hazards regression analysis was used to assess the association of IBD with the risk of overall and cause-specific death, expressed as hazard ratios (HRs) with 95% CIs. An a¼0.05 was considered statistically significant. Table 1 .
RESULTS
Overall Mortality Crohn Disease. A total of 74 deaths occurred in 411 patients with CD compared with 59.2 expected (SMR, 1.25; 95% CI, 0.98-1.57). The crude mortality rate of patients with CD diagnosed from 1970 through 2010 was 9.8 cases per 1000 person-years. The estimated overall survival of patients with CD was 93% after 10 years, 83% after 20 years, 77% after 30 years, and 61% after 40 years ( Figure A) . Although not statistically significant, 38 men died compared with 29.6 expected (SMR, 1.28; 95% CI, 0.91-1.76) and 36 women died compared with 29.6 expected (SMR, 1.22; 0.85-1.68). Mortality risk stratified by age at CD diagnosis was not significantly different (Table 2) . When SMRs were stratified by calendar year at diagnosis, an increased mortality risk in patients with CD diagnosed from 1970 through 1979 was observed (SMR, 1.90; 95% CI, 1.24-2.78). Thereafter, the mortality risk in patients with CD did not differ from that in the US background population (Table 2 ). Using the SMR in the 1970-1979 calendar period as a reference, patients with CD diagnosed from 1990 through 1999 had a significantly decreased risk of dying (P¼.04) ( Figure B ).
Ulcerative Colitis. Among the 484 patients with UC, 77 deaths were observed, significantly less than the 108.1 expected deaths of the US background population (SMR, 0.71; 95% CI, 0.56-0.89).The crude mortality rate of patients with UC diagnosed from 1970 through 2010 was 8.4 cases per 1000 person-years. The estimated overall survival of patients with UC was 94% after 10 years, 86% after 20 years, 77% after 30 years, and 60% after 40 years ( Figure C) . Stratifying SMR by sex showed significantly fewer observed deaths than expected in men (SMR, 0.70; 95% CI, 0.52-0.93). The mortality risk in women was the same as that in the US background population (SMR, 0.73; 95% CI, 0.48-1.05).The mortality risk stratified by age at UC diagnosis was similar to that in the US background population ( Table 2) .
As stratified by calendar period at diagnosis, the risk of dying in patients with UC was comparable with that in the US background population (Table 2 ). There were no significant differences between any 2 of 4 period-specific SMRs (P.05 for all 6 comparisons) ( Figure D ). In the UC cohort, no statistically significant differences in death from any cause were observed (Table 3) .
Cause-Specific Mortality
IBD-Related Mortality
Of the 74 deaths in the CD cohort, 14 (19%) were identified as CD related. Seven patients died of infections related to complicating CD (intestinal fistulizing, perforation, or abscess), accounting for 9% of all deaths in patients with CD. Of the 77 deaths in the UC cohort, 13 (17%) were identified as UC related. Two patients died of CRC. Six patients died of primary sclerosing cholangitis related to UC (decompensated cirrhosis and cholangiocarcinoma), accounting for 8% of all deaths in patients with UC.
DISCUSSION
This population-based inception cohort of patients first diagnosed as having IBD between January 1, 1970, and December 31, 2010, and followed up through June 30, 2016, showed that the overall mortality in patients with CD did not differ significantly from that in the US 2010 background population. The overall mortality rate in patients with UC was lower than the expected mortality rate in the US 2010 background population. Mortality risks due to digestive diseases and respiratory diseases were significantly increased in CD but not in UC. Less than one-fifth of all deaths could be attributed to CD and UC. The present study showed that the overall mortality rates in patients with CD diagnosed from 1970 through 2010 were higher than those in the US general population and in the Olmsted County residents; however, they did not reach statistical significance. An increased risk of dying of digestive diseases (HR, 3.70; 95% CI, 1.24-11.0) remained a significant cause-specific mortality in CD as a previous report of an earlier cohort. 14 However, a change in excess mortality due to respiratory diseases (HR, 2.72; 95% CI, 1.36-5.44) in patients with CD was observed, which was not previously observed. The CD-related mortality seemed to decrease from the previous report 14 from 32% (18 deaths) to 19% (14 deaths). Because most of the CD-related deaths occurred in patients diagnosed from 1970 through 1979 (8 deaths, 57%), the excess risk of dying in this period was also significantly observed. These findings may be explained by an improvement in CD management. Increased use and earlier introduction of immunomodulators during the disease course began to take place in the early 1990s, and biological agents have been used since 1998. Furthermore, a practice of regular CRC surveillance for IBD (especially UC) has been widespread since 1980. Another reason for temporal differences in mortality may be explained by the higher active smoking rate in the patients diagnosed in the 1970s compared with other calendar years. We found that one-third of patients with CD diagnosed in the 1970s were active smokers, whereas the proportion of active smokers in the later calendar periods of diagnosis declined to less than one-fifth. Current smoking at the time of CD diagnosis is a predictor for unfavorable CD outcomes (eg, major abdominal surgery). 22 In addition, cigarette smoking can directly contribute to respiratory diseases. It is worth noting that stopping cigarette smoking may play a role in the improved CD-related mortality and overall survival rates as much as the improved IBD care.
In the UC cohort, we found a significantly decreased overall mortality rate in patients with UC compared with the US background population (SMR, 0.69; 95% CI, 0.54-0.86), whereas the overall UC mortality rate was comparable with that of Olmsted County residents without IBD (HR, 0.89; 95% CI, 0.70-1.14). A previous study from the REP has shown the generalizability of age-and sex-specific mortality rates in their findings to Olmsted County and the entire United States. 17 However, residents of Olmsted County aged 20 to 60 years had lower mortality rates than the US population. 17 Because those ages are common in patients with UC, it may in part explain the lower risk of dying in UC compared with the US general population but not the Olmsted County population. The prevalence of UC-related death in the present study was 17% (13 deaths), which did not differ from the previous report's 19% (12 deaths). We found that only 2.7% of deaths (2 deaths) among patients with UC were caused by CRC, and this low proportion of CRC death is in keeping with our previous report of 8% (5 deaths), as well as a population-based study from Denmark. 11 In contrast, the proportion of deaths from UC-related primary sclerosing cholangitis increased from 8% (1 death) in our previous report to 46% (6 deaths) in the present study. This may explain why the overall UC-related death rate did not decrease. Although there are several studies reporting on IBD mortality from different geographic regions, one must be cautious in comparing results due to different study populations and study designs. For instance, populationbased nationwide registry studies that rely on diagnostic and billing codes have limitations. Deaths caused by IBD could not be verified and included in gastrointestinal disease causes. 10, 12 On the other hand, hospitalbased studies are subject to referral bias because patients with more severe disease are more likely to seek medical attention at referral centers, and this could eventually lead to a higher mortality rate. In the European Collaborative Study Group on Inflammatory Bowel Disease, the mortality risk in patients with CD was 1.8-fold higher than that in the general population. 23 In addition, studies consisting of a mix of prevalent and incident cases would have selection bias for patients with milder disease, and this too could lead to a lower mortality rate. In a prevalence Australian IBD cohort, the overall mortality rate in IBD was lower than expected (SMR, 0.85; 95% CI, 0.74-0.97). 8 The main strength of this study is that all ascertainments of IBD cases were based on strict diagnostic criteria and were derived from a well-defined geographic region. Because of the medical record linkage system (REP), we were able to review all available patient data from the index date of IBD diagnosis until the end of the study period. All the death certificates were retrieved, and the cause of death related to IBD was verified by medical record review rather than by administrative data. For the comparison of mortality between the IBD and non-IBD county cohorts, we had 80% power to detect HRs of 1.52 or greater for CD and 1.43 or greater for UC (a ¼ 0.05). However, there are some limitations in this study. First, the relatively large white population in the region may limit the generalizability of these data to populations with more diverse race/ethnicity. Second, socioeconomic factors are associated with healthy lifestyle and accessibility to health care utilization. Olmsted County had more high schoolegraduated residents and a higher median household income compared with that of the entire US population. 17 This may explain why middle-aged county residents had a slightly lower mortality rate compared with the entire United States. Third, the relatively small number of cause-specific deaths in this study may have contributed to the lack of statistical significance. Fourth, we did not collect data on comorbidities, which may have contributed to the risk of dying. Finally, the information on death certificates was verified by medical record review for cases but not for the comparison cohort; although this would not have affected the estimate of overall mortality risk, it may have affected calculations of cause-specific mortality.
CONCLUSION
This population-based cohort study revealed that the overall mortality rate in patients with CD diagnosed after 1980 did not differ from that in the US background population. The overall mortality rate in patients with UC diagnosed from 1970 through 2010 was lower than the expected mortality rate. For cause-specific mortality, increased risks of dying of digestive diseases and respiratory diseases were observed in CD, but there were no differences in cause-specific mortality in UC.
